According to a media release issued by Dendreon Corp. early this morning, the company will be declaring Chapter 11 bankruptcy but is assuring physicians and patients that sipuleucel-T (Provenge) will continue to remain available during the company’s restructuring. What is a good deal less clear is whether the company will be sold after the restructuring or will continue to operate as a stand-alone entity.
Filed under: Uncategorized | Tagged: Provenge, sipuleucel-T | Leave a comment »
The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to treat patients with metastatic prostate cancer before they have received chemotherapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, England, NICE, Provenge, sipuleucel-T, value | 3 Comments »
According to a media release issued earlier today, Dendreon is planning to make sipuleucel-T (Provenge) available in Europe, beginning with Germany and the United Kingdom. However, the media release is short on any precision regarding the dates of such availability. … READ MORE …
Filed under: Management, Treatment | Tagged: access, Europe, sipuleucel-T | Leave a comment »
An article with the above title by Dr. Michael Glodé (a well-known medical oncologist at the University of Colorado in Denver) appears in the most recent issue of ASCO Connection. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: immunotherapy, sipuleucel-T | 14 Comments »
According to a report on the Bloomberg.com web site, Dendreon “is seeking a buyer after sales of its prostate-cancer treatment failed to meet expectations.” The “New” Prostate Cancer InfoLink has no “inside scoop” on this, but it would be a terrible shame if such an innovative approach to cancer therapy were to go off the market.
Filed under: Uncategorized | Tagged: Provenge, sipuleucel-T | 2 Comments »
The European Medicines Agency’s Committee for Medicinal Products for Human Use today recommended that marketing authorization be approved for sipuleucel-T (Provenge) in the European Union. A final decision by the European Commission is likely later this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, Europe, Provenge, sipuleucel-T | Leave a comment »
There is an interesting report on the OncLive web site of a lecture by Dr. Robert Dreicer given just a few weeks ago and dealing with the sequential and combination use of new agents like abiraterone acetate, enzalutamide and others for the treatment of advanced and progressive forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, combination, enzalutamide, radium-223, sequencing, sipuleucel-T | 14 Comments »
A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, aflibercept, ARN-509, cabazitaxel, cediranib, dasatinib, enzalutamide, radium-223, sipuleucel-T | 6 Comments »
A videotaped expert commentary by Dr. Johann de Bono on the Medscape Oncology web site (with transcript) discusses four therapies (three now approved in the USA) that have recently demonstrated a survival benefit in the treatment of metastatic, castration-resistant prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, cabazitaxel, radium-223, sipuleucel-T | Leave a comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) — improves health outcomes for Medicare beneficiaries … READ MORE …
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a comment »
Dendreon’s production ramp-up for sipuleucel-T (Provenge®) is on track, the company says, with manufacturing expected to be up to full speed by year’s end. All three US-based manufacturing plants will be shipping by then, and treatment with Provenge should be available at hundreds of more locations, according to a Reuters report last week. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: access, Provenge, sipuleucel-T | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 